Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio-Reference-Cited by-同舟云学术

Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio

Published:2020-12 Issue: Volume:54 Page:229-234
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Lee Clara Inkyung^ORCID,Low Siew Kee,Maldonado Ricardo^ORCID,Fox Peter,Balakrishnar Bavanthi,Coulter Sally,de Bruijn Peter,Koolen Stijn L.W.,Gao Bo,Lynch Jodi,Zdenkowski Nicholas,Hui Rina,Liddle Christopher,Mathijssen Ron H.J.,Wilcken Nicholas,Wong Mark,Gurney Howard

Funder

National Health and Medical Research Council

Cancer Institute NSW Sydney West Translational Cancer Research Centre

Roche

Sanofi

Astellas Pharma

Bayer

Boehringer Ingelheim

Pfizer

Novartis

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference34 articles.

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Lancet,2005

2. CYP2D6 and tamoxifen: DNA matters in breast cancer;Hoskins;Nat Rev Canc,2009

3. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma;Murdter;Clin Pharmacol Ther,2011

4. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping;Binkhorst;Canc Treat Rev,2015

5. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients;Helland;Breast Cancer Res,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. THE APPLICATION OF BIOANALYTICAL METHOD OF TAMOXIFEN AND ITS ACTIVE METABOLITES FOR THERAPEUTIC DRUG MONITORING IN BREAST CANCER PATIENTS: A REVIEW;International Journal of Applied Pharmaceutics;2024-05-07

2. Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort;British Journal of Clinical Pharmacology;2023-06-26

3. Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups;Cancers;2021-05-18

4. Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy;Cancers;2021-02-12